US/UK/Canada

Share

Pick a time period -
Tags ( Active)

QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT

NextCell Pharma AB* announces that its subsidiary, QVance AB, has published an article in collaboration with the International Society of Cell and Gene Therapy (ISCT). The article, authored by Dr. Lindsay Davies, CSO at NextCell and co-founder of QVance, was published in Cytotherapy and is based on a global survey examining knowledge on particulates in cell and gene therapy (CGT) products.QVance, founded by cell therapy developers to support other cell therapy developers, aims to become the leading quality analysis company for CGT in the Nordic region. With NextCell’s expertise as a

NextCell Pharma AB participates in BIO-Europe 2024 and welcomes a visit from Minister Ebba Busch

NextCell Pharma AB* proudly announces its participation in BIO-Europe 2024, one of Europe’s most significant partnering conferences in biotechnology and pharmaceutical development. The event will be held at Stockholmsmässan from November 4-6, and is expected to gather over 5,000 leading professionals from around the world.During BIO-Europe, NextCell will be an active part of the Swedish pavilion organized by Business Sweden, providing a unique opportunity to showcase NextCell's advancements and contributions in cell therapy and precision medicine. The company also looks forward to

NextCell publishes its Year-End Report 2023/2024

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2023 – August 31, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.Fourth quarter (2024-06-01 until 2024-08-31) · Operating income amounted to 1,696 (3,947) TSEK, of which Cellaviva amounted to 1,643 (2,758) TSEK. · Net Income amounted to 1,643 (2,

NextCell Pharma invited to present in Tokyo

NextCell Pharma AB's* CEO, Mathias Svahn, has been invited by Business Sweden to the Swedish Embassy in Tokyo, to present the company’s ongoing development at an event on October 8, 2024. The event will focus on innovations in AI and healthcare, where Swedish and Japanese stakeholders will gather to discuss how future healthcare solutions can be developed through collaboration.Mathias Svahn will present NextCell's groundbreaking work in cell therapies and how these can contribute to sustainable and efficient healthcare solutions. The event is part of the initiative “Pioneering the Possible”,

ProTrans highlighted as a promising treatment for type 1 diabetes in Dagens Medicin

NextCell Pharma AB* is proud that their drug candidate ProTrans has been highlighted in Dagens Medicin’s latest edition featuring ongoing research advances in the treatment of type 1 diabetes. ProTrans consists of mesenchymal stromal cells from the umbilical cord and has been investigated in a number of clinical studies at Uppsala University Hospital, where its potential to slow down the progression of the disease has been demonstrated.Articles in Dagens Medicin (2024-09-25) underline the need to protect insulin-producing beta cells and delay the development of type 1 diabetes, an

The first children have been treated in the younger age group of the ProTrans-Young study

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), announces that the first four children in the 7–11 year age group have been treated in the latest phase of the ProTrans-Young study. An additional four children have been screened and are expected to begin their treatment shortly. These advancements mark an important milestone in the progress of the study, which is proceeding faster than anticipated.“There is a high level of interest in the study, and many are signing up from all over the country,” comments Karin Kjellström, research nurse at Uppsala

Broader health benefits of ProTrans in treatment of type 1 diabetes

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), has presented new long-term clinical data at the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting, held in Gothenburg, Sweden. The results show the long-term safety of the treatment, the effect of preserving the patient's own insulin production and more health benefits in patients with type 1 diabetes (T1D), such as lower BMI and blood pressure.A Single Dose of ProTrans Slows Disease Progression for More Than 5 Years. Patients from the Phase II trial have been monitored for

CSO Lindsay Davies Co-Chairs ISCT Europe 2024 Meeting

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), a leader in advanced cell therapy and immunotherapy research, is proud to announce that Dr. Lindsay Davies, the company’s Chief Scientific Officer (CSO) and ISCT Europe Regional Secretary, serves as Co-Chair together with Dr. Massimiliano Gnecchi of the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting, held in Gothenburg, Sweden, from September 4-6."We are thrilled to have Dr. Davies representing NextCell Pharma at such an influential event," says Mathias Svahn, CEO of

NextCell publishes its Interim Report 3 2023/2024

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2023 – May 31, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.Third quarter (2024-03-01 until 2024-05-31) ● Operating income amounted to 2,482 (4,189) TSEK,    of which Cellaviva amounted to 2,442 (3,040) TSEK. ● Net Income amounted to 2,442 (3,

NextCell carries out a directed issue of units to guarantors in connection with the completed rights issue

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of NextCell Pharma AB (publ) (“NextCell” or the “

NextCell’s rights issue oversubscribed

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. NextCell Pharma AB (publ) (”NextCell” or the “Company”) hereby announces the

The paediatric diabetes study gets the green light to treat the age group 7 – 11 years

NextCell Pharma AB (publ) ("NextCell") announces that the Data Safety Monitoring Board for the ProTrans-Young study has recommended the principal investigator, Professor Per-Ola Carlsson, to continue with treatment of children in the younger age group 7 – 11 years. This decision is based on a review of all available safety data from the 36 children and adolescents who have participated in the study so far. The recruitment of the 30 children aged 7-11 will begin in August 2024.The first part of the ProTrans-Young study is a safety part (phase Ib) where all 6 patients aged 7-18 years are

The Board of Directors and management sign in addition to subscription commitments

NextCell Pharma AB (publ) ("NextCell" or the "Company") carries out a rights issue of units of up to approximately SEK 40.1 million, which is covered to approximately 100 percent by subscription and guarantee commitments. The company's Board of Directors, management and key employees, who have previously entered into subscription commitments of up to a total of approximately SEK 1.5 million, have now announced that they will register their interest in subscribing for units for a total of approximately SEK 3.3 million, corresponding to 8.2 percent of the rights issue.In addition to the

NextCell publishes supplement to the prospectus regarding the rights issue

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. NextCell Pharma AB (publ) (”NextCell” or the “Company”) has today published

Cellaviva becomes an independent company under NextCell Pharma

Cellaviva, the stem cell bank operated by NextCell Pharma AB, has announced its transition to an independent company. This strategic move will enable Cellaviva to further focus on its core mission of providing expectant parents with the opportunity to preserve and store valuable stem cells collected from the placenta and umbilical cord. These cells, which would otherwise be discarded post-birth, offer significant potential for future medical treatments and therapies.Since its inception in August 2015, Cellaviva has garnered a growing customer base each year, reflecting increasing awareness

NextCell procures top guarantee in ongoing rights issue

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. NextCell Pharma AB (publ) ("NextCell" or the "Company") announces that the

The subscription period in NextCell’s rights issue commences today

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.  Today, 31 May 2024, the subscription period in NextCell Pharma AB (publ)’

NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. NextCell Pharma AB (publ) (”NextCell” or the “Company”) has prepared an EU

Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years

NextCell Pharma AB ("NextCell" or the "Company") today announces that patients who were treated with a single dose of ProTrans five years ago in the randomized, placebo-controlled phase II study ProTrans-2 have retained significantly higher endogenous insulin production than patients who received placebo. ProTrans treated patients maintained 57% of their endogenous insulin production compared to 15% in the placebo group. The results are in line with NextCell’s previously reported three year data and demonstrates that ProTrans offers a disease-modifying treatment with long-lasting clinically

Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ)

At the Extraordinary General Meeting of NextCell Pharma AB (publ) (“NextCell” or the “company”) on 27 May 2024, the following resolutions were made. All resolutions were in accordance with the proposals presented, which are described in detail in the general meeting documents available on the company’s website, www.nextcellpharma.com. Resolution on amendment of the limits for the number of members of the Board of Directors in the Articles of Association The general meeting resolved, in accordance with the Board of Directors’ proposal, to amend the limits for the number of members of

NextCell publishes its Interim Report 2 2023/2024

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2023 – Februari 29, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.Second quarter (2023-12-01 until 2024-02-29) ● Operating Income amounted to 2,405 (2,734) TSEK, of which    Cellaviva amounted to 2,334 (2,107) TSEK.● Net Income amounted to 2,334 (

Notice of Extraordinary General Meeting in NextCell Pharma AB (publ)

The shareholders of NextCell Pharma AB (publ), Reg. No. 556965-8361 (”NextCell” or the ”company”), are hereby summoned to an Extraordinary General Meeting on Monday, 27 May 2024, 10:00 CEST, in the Novum building, floor 6 (elevator E), Hälsovägen 7, SE-141 57 Huddinge, Sweden.Right to attend In order to attend the Extraordinary General Meeting, shareholders shall be registered in the share register kept by Euroclear Sweden AB as of 17 May 2024. Further, shareholders who wish to participate in the Extraordinary General Meeting must give notice of participation to the company no later than

The Board of Directors of NextCell resolves on a rights issue of units of approximately SEK 40.1 million, subject to approval by an Extraordinary General Meeting

THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. The Board of Directors of NextCell Pharma AB (publ) (”NextCell” or the ”Company”) has

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe